Related Experiment Videos
Pharmacogenomics in colorectal cancer
1Division of Oncology, University of Southern California/Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA 90033, USA.
Seminars in Oncology
|October 3, 2003
Summary
Predicting chemotherapy response and toxicity is crucial. Tumor profiling, including gene and protein expression, can guide treatment decisions for drugs like fluoropyrimidines and platinums, improving patient outcomes.
Area of Science:
- Oncology
- Pharmacogenomics
Background:
- Chemotherapy administration aims to predict treatment response and toxicity.
- Tumor profiling technologies measure protein and gene expression, and genetic polymorphisms.
Purpose of the Study:
- To explore the potential of tumor profiling in predicting chemotherapy outcomes.
- To identify specific markers that predict response to chemotherapeutics.
Main Methods:
- Utilizing technology for tumor profiling.
- Measuring protein expression, gene expression levels, and genetic polymorphisms.
- Analyzing markers associated with fluoropyrimidines and platinums.
Main Results:
- Specific markers have been identified that predict outcomes for fluoropyrimidines and platinums.
- Tumor profiling offers a method to assess individual patient response and toxicity.
Conclusions:
- Prospective clinical trials are needed to validate the benefits of tumor profiling.
- Patient-specific tumor profiling is expected to improve chemotherapy response and reduce toxicity.